PATH Pneumococcal Vaccine Study
Help VEC researchers evaluate a new vaccine to protect against 25 strains of streptococcus pneumoniae bacteria!
Why are we doing this study?
Researchers at the VEC and the University of British Columbia will help to evaluate a new vaccine to protect against 25 strains of streptococcus pneumoniae bacteria. There is a vaccine approved in Canada that protects against the diseases caused by 20 types of SP. However, there are many types of SP responsible for diseases not covered by this vaccine.
PATH Pneumococcal Vaccine Study participants will be randomly assigned to receive a new vaccine called IVT PCV-25 (a vaccine against 25 types of pneumococcus) or Prevnar 20™ (an approved pneumococcal vaccine used in Canada to help protect against 20 types of streptococcus pneumoniae). Participation will involve four visits at the VEC and one phone call during a period of six months. The total time commitment of the study is about 3.5 to 4.5 hours. We will perform a screening (general health and medical history check) at the first visit and provide the vaccine at the second visit, and we will collect a blood sample and ask questions about your health at all visits.